Cohort Study on Refractive Errors in Preschool Children (PREC)
Refractive error is a common visual disorder encompassing myopia, hyperopia, astigmatism and other subtypes. Refractive error in preschool children refers to refractive abnormalities occurring during the preschool period (0-6 years old). Studies conducted across diverse regions and populations report that the prevalence of refractive error among preschool children ranges approximately from 10% to 30%, with this proportion showing a gradual upward trend in recent years. Existing evidence suggests that preschool refractive status is correlated with multiple ocular and systemic diseases. Furthermore, the preschool years represent a highly sensitive window for children's visual development; uncorrected refractive errors at this stage can disrupt visual maturation and induce permanent visual impairment. Accordingly, identifying the full spectrum of comorbidities associated with preschool refractive error, alongside implementing early diagnosis and intervention, is clinically critical.
Nevertheless, substantial challenges persist in the clinical management of preschool refractive errors: the complete comorbidity spectrum remains undefined, its natural history has not been fully elucidated, and high-quality evidence-based guidelines for refractive correction and visual rehabilitation are lacking. Establishing a prospective cohort of preschool children with refractive errors is therefore of great significance for clarifying disease progression and risk factors, generating evidence for standardized refractive interventions and visual rehabilitation protocols, and ultimately preventing visual impairment and improving quality of life in this vulnerable pediatric population.
Our research team has previously completed preliminary investigations characterizing myopia in preschoolers. Building on this foundational work, we aim to construct a dedicated cohort of preschool children with refractive errors to delineate the natural history, progression risks and comorbidity profiles of preschool refractive error, and explore effective refractive correction and visual rehabilitation approaches for affected young children.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Xiao Yang
- Phone Number: 13760766303
- Email: yangx_zoc@163.com
Study Locations
-
-
Guanzhou
-
Guangdong, Guanzhou, China, 510060
- Zhongshan Ophthalmic Center Sun Yat-Sen University
-
Contact:
- Xiao Yang
- Phone Number: 13760766303
- Email: yangx_zoc@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Onset of refractive error occurs during preschool age (0-6 years old) supported by retrievable medical records;
- Spherical equivalent power ≤ -0.50 D or ≥ +3.00 D in any meridian;
- Legal guardians agree to participate and sign written informed consent.
Exclusion Criteria:
Children unable to cooperate with examinations and follow-up visits.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Refractive error
Refractive error in preschool children
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ocular Biometry Parameters
Time Frame: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
A set of objective ocular structural measurements mainly including axial length (AL), alongside corneal curvature, anterior chamber depth, lens thickness and vitreous chamber depth.
Axial length, the core indicator in this study, refers to the linear distance from the anterior corneal surface to the retinal pigment epithelium, which is closely associated with the onset and progression of refractive errors in preschool children.
All biometric indices will be measured using standardized ophthalmic biometry equipment at each follow-up visit to dynamically observe the developmental rules of ocular dimensions and their correlation with refractive status.
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BCVA
Time Frame: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Visual Acuity Examination
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
Contrast Sensitivity
Time Frame: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
CSF
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
SER
Time Frame: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Spherical Equivalent Refraction，Comprehensive index reflecting overall ocular refractive status, integrating myopia, hyperopia and astigmatism.
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
WES (Whole Exome Sequencing)
Time Frame: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Genetic sequencing results of all protein-coding regions to detect gene variants related to refractive disorders.
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
|
OCT
Time Frame: From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
OCT Imaging Findings
|
From date of enrollment until the date of loss to follow-up from any cause, whichever came first, assessed up to 36 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023KYPJ340-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.